Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial<a class="excerpt-read-more" href=" More ...

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according ...

The scientists involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data ...

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top ...

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...